Panacea Biotec Share Price Jumped 9% After Completing Phase III Enrollment for Dengue Vaccine

Panacea Biotec share price (NSE: PANACEABIO) surged up to 9.3% on the BSE on Thursday, touching an intraday high of ₹418.35. The rally came after the company announced that it has completed participant enrollment for the Phase III clinical trial of its dengue vaccine candidate, DengiALL.

At around 9:39 am, the stock was trading nearly 9% higher at ₹417.95, even as the Sensex slipped 0.12%.

About The Dengue Vaccine Dengiall

DengiALL is a single-dose, tetravalent dengue vaccine designed to protect against all four dengue virus types (DEN-1 to DEN-4). The vaccine uses weakened forms of the virus to safely prepare the immune system to fight real infections.

This approach is important because infection with one dengue strain can increase the risk of severe illness if a person later catches another strain. DengiALL aims to provide balanced protection against all four types at once.

Trial Progress And Next Steps

Panacea Biotec said it has enrolled 10,335 participants in the Phase III study. These participants will now be monitored for two years after dosing to evaluate the vaccine’s safety, immune response, and effectiveness.

The company expects DengiALL to become India’s first indigenous single-shot dengue vaccine, with a possible market launch by 2027.

Stock Details and Performance

• Current price: ₹414.55 (up 7.94%)
• Market capitalisation: ₹2,559.97 crore
• 52-week high: ₹581.90
• 52-week low: ₹282.15

Despite today’s rally, the stock has fallen around 15% over the past year, while the Sensex has gained 8.7% during the same period.

Read More:8th CPC, DA Hikes and Pension Reforms: 10 Big Changes for Central Govt Employees in 2025!

Development History Of Dengiall

The development of DengiALL began in 2006 through a collaboration between Panacea Biotec and the US National Institutes of Health (NIH).

• Phase I/II trials in India were completed with 3 years of safety follow-up by 2020
• In March 2022, Panacea Biotec signed an MoU with ICMR for Phase III trials
• Phase III trials were approved by the DCGI and conducted at 19 sites across India

Conclusion

Panacea Biotec’s sharp stock rise reflects investor optimism after the successful completion of Phase III enrollment for DengiALL. While the stock has underperformed the broader market over the past year, progress on a potential first-of-its-kind dengue vaccine could be a key long-term trigger for the company.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.